ABILIFY news

What is ABILIFY (aripiprazole)?
ABILIFY is a prescription medicine used as an add-on treatment to an antidepressant for adults with Major Depressive Disorder who had an inadequate response to antidepressant therapy. What is depression?Moncler hat
Depression is a common but serious medical condition Symptoms may include sadness, loss of interest in activities you once enjoyed, loss of energy, difficulty concentrator or making decisions, feelings of worthlessness or excessive guilt, insomnia or excessive sleep, a change in appetite causing weight loss or gain, or thoughts of death or suicide. These could be depression symptoms if they interfere with daily life at home, at work, or with friends and last most of the day. nearly every day for at least 2 weeks. What is the most important information that I should know about antidepressant medicines, depression, and other serious mental illnesses?
• Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults
• Depression and serious mental illnesses are the most important causes of suicidal thoughts and actions
For more information, see the Prescribing Information and the Medication Guide called Antidepressant Medicines. Depression and Other Serious Mental Illnesses, and Suicidal Thoughts or Actions
Who should NOT take ABILIFY?Moncler shoes
People who are allergic to ABILIFY or to any substance that is in iL Allergic reactions have ranged Irom rash, hives and itching to difficulty breathing and swelling of the face. lips, or tongue. Please talk with your healthcare professional. What is the most important information that I should know about ABILIFY? Elderly patients, diagnosed with psychosis as a result of dementia (for example, an inability to perform daily activities as a result of increased memory loss), and who are treated with antipsychotic medicines including ABILIFY, are at an increased risk of death when compared to patients who are treated with a placebo (sugar pill). ABILIFY is not approved for the treatment of patients with dementia-related psychosis.